PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE

CONVEYING PARTY DATA

Name	Execution Date
Torrey Pines Institute for Molecular Studies	02/24/1998

RECEIVING PARTY DATA

Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government	
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)	
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980	
City:	Bethesda	
State/Country:	MARYLAND	
Postal Code:	20892-7980	

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	5641861

CORRESPONDENCE DATA

Fax Number: (301)480-0272

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: edison@nih.gov

Correspondent Name: Director, DEITR

Address Line 1: NIH, 6705 Rockledge Drive, Suite 310

Address Line 2: MSC 7980

Address Line 4: Bethesda, MARYLAND 20892-7980

NAME OF SUBMITTER: Director, DEITR, NIH

Total Attachments: 1

source=5641861-p0001 - p0002#page2.tif

PATENT REEL: 021194 FRAME: 0575

LICENSE TO THE U.S. GOVERNMENT

2428601-950001

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a non-exclusive, nontransferable, irrevocable, paid up license to practice or have practiced on its behalf throughout the world for governmental purposes the following subject invention:

TPIMS Disclosure Number:

95-02

Disclosure Title:

Mu and kappa opioid receptor ligands: agonists and

antagonists

Disclosure Inventors:

Dooley & Houghten

Patent Application

Serial No.:

08/472,219 and 08/487,006

Filing Date:

June 7, 1995

Patent Title:

Novel kappa receptor selective ligands: agonists and

Date

antagonists

Novel mu opioid receptor ligands: agonists & antagonists

2-24-98

Inventors:

Dooley & Houghten

U.S. Patent Number:

5,610,271 and 5,641,861

U.S. Patent Issue Date:

Peggy Totzke

RECORDED: 07/07/2008

March 11, 1997 and June 24, 1997

As indicated in the disclosure, this subject invention was conceived or first actually reduced to practice in performance of a government funded project, National Institutes of Health Grant

Principal rights to this subject invention have been assigned to the Licensor, namely, Torrey Pines Institute for Molecular Studies, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed

Chief Financial and Administrative Officer

Torrey Pines Institute for Molecular Studies

PATENT REEL: 021194 FRAME: 0576